Bank of America raises target for Johnson & Johnson stock

Published on 10/05/2026 at 13:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Icotyde forecast reaches USD 4.50 billion from USD 2.40 billion. Johnson & Johnson stock costs EUR 228.75 on October 5, 2026, versus EUR 227.50.

Pop art comic book illustration of a large beige adhesive bandage roll centered on a halftone dot background in cyan and magenta, bold black comic outlines, yellow starburst and red lightning bolt elements radiating outward, flat primary colors of red blu — Johnson Consumer Health im Pop Art Stil, US4781601046 Pflasterrolle mit Halftone und Comic Outlines, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at EUR 228.75 at Lang & Schwarz on October 5, 2026 at 1:17 p.m. CEST, plus 0.55 percent versus the prior close of EUR 227.50. According to Yahoo Finance on October 1, 2026, Bank of America analyst Jason Gerberry raised the price target from USD 263.00 to USD 278.00 on September 29 while keeping a Neutral rating.

Bank of America sees limited near-term upside

The target change followed a sharp increase in Bank of America's peak-sales forecast for Icotyde, Johnson & Johnson's oral psoriasis treatment. Yahoo Finance reported that the forecast rose to USD 4.50 billion from USD 2.40 billion, while the bank cited a physician dermatology survey as part of its analysis.

Bank of America expects third-quarter sales of USD 25.50 billion and adjusted earnings per share of USD 2.53, below the USD 2.87 consensus cited in the same October 1 report. That split gives investors a clear tension to track: stronger drug potential against near-term research costs.

Quarterly figures set the next test

For the second quarter of fiscal 2026, Yahoo Finance lists revenue of USD 25.31 billion and earnings of USD 5.53 billion. The company is scheduled to report third-quarter 2026 results on October 13, 2026, giving the market a near-term checkpoint for sales, earnings and pipeline spending.

That date matters because the current analyst debate is unusually specific. The USD 2.53 earnings-per-share forecast is below the USD 2.87 consensus, even as Icotyde's peak-sales estimate has moved from USD 2.40 billion to USD 4.50 billion.

Target remains below the euro quote

GuruFocus reported on September 10, 2026 that HSBC kept a Buy rating and raised its target from USD 290.00 to USD 320.00. The differing ratings show why the October earnings release may matter more than a single target change: HSBC remains constructive, while Bank of America sees a USD 278.00 target and Neutral rating.

Johnson & Johnson's primary listing is on the NYSE under ticker JNJ, according to TradingView. The finance quote shows a market capitalization of USD 617.0 billion and a 52-week range of USD 182.94 to USD 281.07 as of October 2, 2026.

Johnson and Johnson stock holds above prior close

Johnson & Johnson was trading at EUR 228.75 at Lang & Schwarz on October 5, 2026 at 1:17 p.m. CEST, up EUR 1.25 or 0.55 percent versus the EUR 227.50 prior close at Lang & Schwarz from October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.